Apoptosis-based therapies

By John Calvin Reed. Nature reviews. Drug discovery, 2002

651 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Targeting proteases: successes, failures and future prospects (2006, background): “As such, preventing protease activation could be an attractive area for potential new therapeutics, and is particularly amenable to RNAi approache”
Bcl-2 family proteins and cancer (2008, background): “…releasing proteins that participate in caspase activation (for example, cytochrome c) and that neutralize endogenous inhibitors of caspases (for example, SMAC; OMI/Htra2, which inhibit IAPs), as well as unleashing several mediators of Oncogene caspase-independent necrotic cell death (Reed, 2002).”
Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis. (2004, background): “marrow stores each day (60); an equal number die an apoptotic death, thus the numbers of circulating cells remain constant.”